XPO1 and acute myeloid leukemia: A 2024 phase I/II trial of selinexor + azacitidine + venetoclax in NPM1-mutant AML reported a 50% complete remission (CR)/CR with incomplete hematologic recovery (CRh) rate, underscoring the utility of targeting XPO1 to disrupt bone-marrow niche support for AML blasts (Sweet and Cluzeau, 2025).